Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
20 / 100
Facteurs de risque
The tender explicitly states it is not a public procurement but an open-house model. Legal remedies may be different (s...
No estimated value or volume disclosed; revenue potential is uncertain.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of pharmaceutical products with active substances Cinnarizin and Dimenhydrinat (ATC N07CA22)
- Non-exclusive discount agreements under SGB V §130a Abs. 8
Afficher le résumé complet
This is an open-house model for non-exclusive discount agreements on pharmaceutical products Cinnarizin and Dimenhydrinat (ATC N07CA22) with AOK Bayern. It is not a competitive procurement; any qualified pharmaceutical company may enter into identical, non-negotiable discount agreements. The contract term runs from 01.06.2025 to 31.05.2027, with possible termination. Submission is either in paper form (two copies) or electronically with a qualified electronic signature. Eligibility is limited to pharmaceutical companies that submit a signed declaration of reliability. No estimated value, award criteria, or competitive selection is involved.
Risques
The tender explicitly states it is not a public procurement but an open-house model. Legal remedies may be different (s...
No estimated value or volume disclosed; revenue potential is uncertain.
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Eligibility
- Only pharmaceutical companies are eligible
Administrative
- Must submit a signed declaration of reliability
- Contract must be submitted in two paper copies or electronically with qualified electronic signature
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Non-exclusive discount agreements for pharmaceutical products containing the active substances Cinnarizin and Dimenhydrinat (ATC N07CA22). All qualified pharmaceutical companies may join.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Afficher les données TED originales
Description TED originale
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Détails de la procédure
- Date de publication
- 15 Apr 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 248752-2025
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
20 / 100
Facteurs de risque
The tender explicitly states it is not a public procurement but an open-house model. Legal remedies may be different (s...
No estimated value or volume disclosed; revenue potential is uncertain.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications